- In February 2024, CD Formulation announced the launch of its innovative oral thin film (OTF) drug delivery platform designed to enhance the bioavailability and patient compliance of various therapeutics. This novel system enables rapid drug absorption through the oral mucosa, bypassing first-pass metabolism and offering a convenient alternative for populations with swallowing difficulties. The OTF technology is expected to benefit a broad range of pharmaceutical applications, including pain management, CNS disorders, and pediatric care
- In 2023, Acacia Pharma introduced Barhemsys and Amisulpride as primary antiemetics for managing PONV. Barhemsys, an intravenous selective dopamine D2 and D3 receptor antagonist, effectively prevents and treats PONV, gaining regulatory approval in the US and Europe for its high efficacy
- In 2023, Roche developed a patient-controlled analgesia (PCA) system for PONV. This system administers opioids and antiemetics via a pump, significantly reducing PONV incidence and enhancing patient satisfaction
